Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 8/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21220171 | 0.83 | MEN1 (0.40) | HDAC4MEN1KMT2A | |
| SCHEMBL29686599 | 0.79 | ATF4 (0.35) | ATF4HDAC4 | |
| SCHEMBL22362684 | 0.78 | LMNA (0.48) | KMT2AHSD11B1 | |
| SCHEMBL29525089 | 0.77 | DRD2 (0.47) | ATF4MEN1KMT2AHSD11B1ALDH1A1 | |
| SCHEMBL29525214 | 0.76 | ALOX15 (0.40) | HDAC4KMT2AHSD11B1ALOX15TSHR | |
| SCHEMBL15258671 | 0.74 | HDAC3 (0.47) | ATF4HDAC4PTGS2KMT2AHSD11B1 | |
| SCHEMBL25386467 | 0.72 | PKM (0.39) | ATF4MEN1KMT2A | |
| SCHEMBL22613807 | 0.72 | CDH1 (0.48) | KMT2A | |
| SCHEMBL22614325 | 0.72 | POLB (0.43) | MEN1KMT2AALDH1A1 | |
| SCHEMBL29686842 | 0.72 | RAB9A (0.46) | MEN1KMT2ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11242327-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200270221-A1 | ANALGESIC COMPOUNDS | KTHERA, LLC | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270221-A1 | ANALGESIC COMPOUNDS | INA, IK, ACHE | ATF4 2947/4885HDAC4 4010/4885PTGS2 22/4885 |
| US-11242327-B2 | Analgesic compounds | INA, IK, ACHE | ATF4 2947/4885HDAC4 4010/4885PTGS2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.